Many Patients Don't Receive Indicated Targeted NSCLC Therapy Many Patients Don't Receive Indicated Targeted NSCLC Therapy
The rates of use of targeted therapy among patients with EGFR- and ALK-mutations also varied across the US, dropping below 20% in some states.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Managing Patients With Early-Stage NSCLC: Always Bet With the Patient Managing Patients With Early-Stage NSCLC: Always Bet With the Patient
Liza Villaruz, MD, puts a mentor ' s piece of advice into practice.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Shifting the Perspective of Therapy Options in Early-Stage NSCLC Shifting the Perspective of Therapy Options in Early-Stage NSCLC
Liza Villaruz, MD, considers how her perspective on early-stage non –small cell lung cancer has changed over time.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2023 Category: Consumer Health News Tags: None MDAngle Source Type: news
Early-Stage Non-Small Cell Lung Cancer: Mitigating the Rigors of Therapy Early-Stage Non-Small Cell Lung Cancer: Mitigating the Rigors of Therapy
Mark Socinski, MD, considers the potential means to identify patients with lung cancer who may not need adjuvant therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
A Look Back at the Rapidly Evolving Treatment Landscape for Early-Stage NSCLC A Look Back at the Rapidly Evolving Treatment Landscape for Early-Stage NSCLC
Mark Socinski, MD, recalls the limited scope of lung cancer staging that he witnessed early in his career.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Early-Stage Non-Small Cell Lung Cancer: Advice to Oncologists Beginning Their Careers Early-Stage Non-Small Cell Lung Cancer: Advice to Oncologists Beginning Their Careers
Thomas Stinchcombe, MD, remarks on the costs of an excess of professional aspiration.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Early-Stage Non-Small Cell Lung Cancer: Addressing the Imperfections Early-Stage Non-Small Cell Lung Cancer: Addressing the Imperfections
Thomas Stinchcombe, MD, reflects on the successes and deficiencies of treatment for early-stage non-small cell lung cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Thinking Big Picture in the Management of Patients With Early-Stage Non-Small Cell Lung Cancer Thinking Big Picture in the Management of Patients With Early-Stage Non-Small Cell Lung Cancer
Kristin Higgins, MD, offers advice to early-career oncologists.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Witnessing Advances in Management Options for Patients With Early-Stage Non-Small Cell Lung Cancer Witnessing Advances in Management Options for Patients With Early-Stage Non-Small Cell Lung Cancer
Kristin Higgins, MD, thinks back to early experiences in treating patients with early-stage non-small cell lung cancer (NSCLC) and the advances that have been made since.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
FDA Approves Keytruda (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
Approval based on KEYNOTE-091 trial, which demonstrated a clinically meaningful improvement in disease-free survival with KEYTRUDA in these patients following surgical resection and platinum-based chemotherapy versus placebo
Approval marks fifth... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 27, 2023 Category: Drugs & Pharmacology Source Type: news
FDA OKs Pembrolizumab for Adjuvant Treatment of NSCLC FDA OKs Pembrolizumab for Adjuvant Treatment of NSCLC
The agency expanded the indication for pembrolizumab to the adjuvant setting for patients with stage IB-IIIA NSCLC following surgery and platinum-based chemo.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA OKs Adjuvant Pembrolizumab for NSCLC
(MedPage Today) -- The FDA has approved pembrolizumab (Keytruda) as an adjuvant therapy following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer (NSCLC), Merck announced.
The... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 27, 2023 Category: American Health Source Type: news
FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 26, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
ICI Survival Gains 'Less Impressive' in Older Lung Cancer Patients
(MedPage Today) -- The introduction of immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) in 2015 has resulted in meaningful survival gains for younger patients, but gains were far more modest among older patients... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 26, 2023 Category: Primary Care Source Type: news
Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patients
(MedPage Today) -- The introduction of immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) in 2015 has resulted in meaningful survival gains for younger patients, but gains were far more modest among older patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 26, 2023 Category: Hematology Source Type: news
